N4 Pharma PLC Update on Nuvec® process improvements (2156B)
29 Enero 2020 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 2156B
N4 Pharma PLC
29 January 2020
29 January 2020
N4 Pharma Plc
("N4 Pharma" or the "Company")
Update on Nuvec(R) process improvements
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide an update on the progress of
its work to improve the dispersion of Nuvec(R), details of which
were announced in the Company's Interim Results on 18 September
2019.
The first two stages of phase one of the in vitro work have now
been completed. The Company has manufactured a new batch of
Nuvec(R) using an improved process and has successfully
demonstrated that the Nuvec(R) particle can be effectively and
repeatedly dispersed into a more monodisperse formulation, prior to
the addition of DNA. The Company expects that this more
monodisperse formulation will result in a more even distribution of
DNA across the Nuvec(R) nanoparticles, thereby resulting in a more
monodisperse formulation of DNA loaded Nuvec(R).
A number of techniques are available to measure particle size
distribution, including dynamic light scattering, laser diffraction
and transmission electron microscopy (TEM). The Company has
compared these nanoparticle measurement techniques to ensure a full
understanding of the extent of agglomeration of Nuvec(R). N4
Pharma's analysis of these techniques has confirmed that TEM
provides a robust assessment of the size and morphology of
individual nanoparticles and that laser diffraction is a more
suitable and consistent process to measure Nuvec(R) dispersion in
an aqueous solution and to define the extent of agglomeration.
Using TEM and laser diffraction the Company has been able to more
accurately measure the size of individual nanoparticles and
quantify the levels of dispersion seen for Nuvec(R).
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"The work highlighted in the Interim Results is moving forward
well and we are pleased to have been able to produce a more
disperse form of Nuvec(R) prior to the addition of DNA.
We will now move forward with the next stage of the work to
investigate how to add DNA to this new more disperse Nuvec(R) in
order to maintain this improved level of dispersion prior to
injection.
We very much appreciate the support of our shareholders as we
undertake this process improvement work and will provide further
updates in due course."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR
Georgia Smith Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESBPMRTMTJTBAM
(END) Dow Jones Newswires
January 29, 2020 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024